Aditxt, Inc.

ADTX

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ADTX
CIK0001726711
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219
Website aditxt.com
Phone909-488-0844
CEOAmro Albanna
Employees60

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$55,323.00
Pre-Tax Income$-26.10 million
Net Income$-26.10 million
Net Income to Common$-31.33 million
EPS$-44.53
View All
Balance Sheet
Cash$476,416.00
Assets$31.22 million
Liabilities$15.46 million
Common Equity$16.59 million
Liabilities & Equity$31.22 million
View All
Cash Flow Statement
Calculations
NOPAT$-15.36 million
EBITDA$-18.23 million
Price to EarningsN/A
Price to Book$0.06
ROE-204.37%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

MOUNTAIN VIEW, Calif., June 26, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.

Article Link

Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

MOUNTAIN VIEW, Calif., June 09, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt’s Board of Directors.

Article Link

Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

MOUNTAIN VIEW, Calif., June 05, 2025--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt"), a social innovation platform accelerating promising health innovations, today announced that its CEO Amro Albanna will be joined for tomorrow’s Aditxt Weekly Update by Dr. Friedrich Kapp, Chris Mitton, and Evofem Biosciences’ CEO Saundra Pelletier to discuss progress in immune therapy, early disease detection and women’s health, respectively.

Article Link

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dat

Article Link

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

MOUNTAIN VIEW, Calif., May 19, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc.

Article Link